Physician profile
John Ha
NPI 1053438846
$1,867.81
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $666 · 2021: $359 · 2022: $119 · 2023: $63.75 · 2024: $16.27 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,151.71 | 2019-2022 | |
| Lilly USA, LLC | $188.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.94 | 2019-2022 | |
| Medtronic, INC. | $119.86 | 2025 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $80.02 | 2023-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.35 | 2020 | |
| Pfizer INC. | $39.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.23 | 2019-2020 | |
| Melinta Therapeutics, LLC | $30.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.43 | 2020 | |
| Abbott Laboratories | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.